SCHEMBL5823192

SCHEMBL5823192

O=P(Oc1ccc(Cl)cc1Cl)(Oc1ccc(Cl)cc1Cl)Sc1ccc(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.44
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TTR P02766 3/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
NR1I2 O75469 1/20 0.40
LMNA P02545 1/20 0.40
PGR P06401 1/20 0.40
HSP90AA1 P07900 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
HSPA5 P11021 1/20 0.40
CBR1 P16152 1/20 0.40
TBXA2R P21731 1/20 0.40
SLC6A2 P23975 1/20 0.40
AGTR1 P30556 1/20 0.40
SLC6A3 Q01959 1/20 0.40
ITGB2 P05107 1/20 0.39
ICAM1 P05362 1/20 0.39
ITGAL P20701 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4372626 0.77 TDP1 (0.51) TDP1MEN1KMT2ATTRMAPT
SCHEMBL29892533 0.77 TDP1 (0.51) TDP1MEN1KMT2ATTRMAPT
SCHEMBL9493767 0.76 TDP1 (0.50) TDP1MEN1KMT2ATTRMAPT
SCHEMBL1368776 0.76 TDP1 (0.50) TDP1MEN1KMT2ATTRMAPT
SCHEMBL3235427 0.74 TDP1 (0.49) TDP1MEN1KMT2ATTRMAPT
SCHEMBL11101053 0.74 TDP1 (0.49) TDP1MEN1KMT2ATTRMAPT
SCHEMBL9494486 0.74 TDP1 (0.49) TDP1MEN1KMT2ATTRMAPT
SCHEMBL12262059 0.74 TDP1 (0.53) TDP1MEN1KMT2ATTRMAPT
SCHEMBL4372630 0.74 INPPL1 (0.52) TDP1TTRMAPTHPGDNR1I2
SCHEMBL9341735 0.73 TDP1 (0.60) TDP1MEN1KMT2AHPGDNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3739785-B2 2006-01-25 JP claimed
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES FROEHLER BRIAN (US) 2004-12-30 US claimed
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines FROEHLER BRIAN (US) 2003-09-11 US claimed
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines ISIS PHARMACEUTICALS, INC. 2003-05-22 US claimed
EP-0637965-B1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES ISIS PHARMACEUTICALS INC (US) 2002-10-16 EP claimed
US-5792608-A Nuclease stable and binding competent oligomers and methods for their use GILEAD SCIENCES, INC. (US) 1998-08-11 US claimed
US-5645985-A USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS GILEAD SCIENCES, INC. (US) 1997-07-08 US claimed
US-5594121-A DETECT VIRUSES, DISEASES GILEAD SCIENCES, INC. (US) 1997-01-14 US claimed
EP-0695306-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES GILEAD SCIENCES, INC. (US) 1996-02-07 EP claimed
EP-0637965-A4 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. GILEAD SCIENCES INC (US) 1996-01-24 EP claimed
EP-0637965-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1995-02-15 EP claimed
WO-1994024144-A2 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES GILEAD SCIENCES, INC. (US) 1994-10-27 WO claimed
WO-1993010820-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1993-06-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030170680-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 TDP1 70/4885MEN1 3158/4885KMT2A 4220/4885
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES NUDT1, DHX15, DDX5 TDP1 70/4885MEN1 3158/4885KMT2A 4220/4885
US-20030096980-A1 Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines NUDT1, DHX15, DDX5 TDP1 70/4885MEN1 3158/4885KMT2A 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.